 LA JOLLA, Calif., Nov. 10, 2020 GLOBE NEWSWIRE -- Equillium, Inc. Nasdaq: EQ, a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020. 